These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

151 related items for PubMed ID: 17059881

  • 1. Dopamine D2 receptor occupancy by risperidone: implications for the timing and magnitude of clinical response.
    Catafau AM, Corripio I, Pérez V, Martin JC, Schotte A, Carrió I, Alvarez E.
    Psychiatry Res; 2006 Dec 01; 148(2-3):175-83. PubMed ID: 17059881
    [Abstract] [Full Text] [Related]

  • 2. Striatal dopamine D2 receptor binding of risperidone in schizophrenic patients as assessed by 123I-iodobenzamide SPECT: a comparative study with olanzapine.
    Schmitt GJ, Meisenzahl EM, Dresel S, Tatsch K, Rossmüller B, Frodl T, Preuss UW, Hahn K, Möller HJ.
    J Psychopharmacol; 2002 Sep 01; 16(3):200-6. PubMed ID: 12236625
    [Abstract] [Full Text] [Related]

  • 3. Iodine-123-iodobenzamide SPECT assessment of dopamine D2 receptor occupancy in riperidone-treated schizophrenic patients.
    Dresel S, Tatsch K, Dähne I, Mager T, Scherer J, Hahn K.
    J Nucl Med; 1998 Jul 01; 39(7):1138-42. PubMed ID: 9669383
    [Abstract] [Full Text] [Related]

  • 4. Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychotics.
    Tauscher J, Hussain T, Agid O, Verhoeff NP, Wilson AA, Houle S, Remington G, Zipursky RB, Kapur S.
    Am J Psychiatry; 2004 Sep 01; 161(9):1620-5. PubMed ID: 15337652
    [Abstract] [Full Text] [Related]

  • 5. A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone.
    Remington G, Mamo D, Labelle A, Reiss J, Shammi C, Mannaert E, Mann S, Kapur S.
    Am J Psychiatry; 2006 Mar 01; 163(3):396-401. PubMed ID: 16513859
    [Abstract] [Full Text] [Related]

  • 6. Subjective experience and striatal dopamine D(2) receptor occupancy in patients with schizophrenia stabilized by olanzapine or risperidone.
    de Haan L, Lavalaye J, Linszen D, Dingemans PM, Booij J.
    Am J Psychiatry; 2000 Jun 01; 157(6):1019-20. PubMed ID: 10831489
    [Abstract] [Full Text] [Related]

  • 7. [123I]IBZM SPECT for imaging of striatal D2 dopamine receptors in 56 schizophrenic patients taking various neuroleptics.
    Klemm E, Grünwald F, Kasper S, Menzel C, Broich K, Danos P, Reichmann K, Krappel C, Rieker O, Briele B, Hotze AL, Möller HJ, Biersack HJ.
    Am J Psychiatry; 1996 Feb 01; 153(2):183-90. PubMed ID: 8561197
    [Abstract] [Full Text] [Related]

  • 8. Striatal dopamine-2 receptor occupancy in psychotic patients treated with risperidone.
    Küfferle B, Brücke T, Topitz-Schratzberger A, Tauscher J, Gössler R, Vesely C, Asenbaum S, Podreka I, Kasper S.
    Psychiatry Res; 1996 Nov 25; 68(1):23-30. PubMed ID: 9027930
    [Abstract] [Full Text] [Related]

  • 9. Dopamine D(2) receptor blockade in schizophrenia.
    Bressan RA, Jones HM, Ell PJ, Pilowsky LS.
    Am J Psychiatry; 2001 Jun 25; 158(6):971-2. PubMed ID: 11384924
    [No Abstract] [Full Text] [Related]

  • 10. Dopamine D2 receptor occupancy by olanzapine or risperidone in young patients with schizophrenia.
    Lavalaye J, Linszen DH, Booij J, Reneman L, Gersons BP, van Royen EA.
    Psychiatry Res; 1999 Nov 08; 92(1):33-44. PubMed ID: 10688158
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Occupancy of dopamine D2 receptors by the atypical antipsychotic drugs risperidone and olanzapine: theoretical implications.
    Frankle WG, Gil R, Hackett E, Mawlawi O, Zea-Ponce Y, Zhu Z, Kochan LD, Cangiano C, Slifstein M, Gorman JM, Laruelle M, Abi-Dargham A.
    Psychopharmacology (Berl); 2004 Oct 08; 175(4):473-80. PubMed ID: 15083259
    [Abstract] [Full Text] [Related]

  • 13. Comfort, self-confidence, safety, and dopamine D2 receptor occupancy by antipsychotics.
    de Haan L, Lavalaye J, Booij J, Linszen D.
    Am J Psychiatry; 2005 Aug 08; 162(8):1544-5. PubMed ID: 16055785
    [No Abstract] [Full Text] [Related]

  • 14. In vivo effects of olanzapine on striatal dopamine D(2)/D(3) receptor binding in schizophrenic patients: an iodine-123 iodobenzamide single-photon emission tomography study.
    Dresel S, Mager T, Rossmüller B, Meisenzahl E, Hahn K, Möller HJ, Tatsch K.
    Eur J Nucl Med; 1999 Aug 08; 26(8):862-8. PubMed ID: 10436199
    [Abstract] [Full Text] [Related]

  • 15. A cross-sectional study of plasma risperidone levels with risperidone long-acting injectable: implications for dopamine D2 receptor occupancy during maintenance treatment in schizophrenia.
    Ikai S, Remington G, Suzuki T, Takeuchi H, Tsuboi T, Den R, Hirano J, Tsunoda K, Nishimoto M, Watanabe K, Mimura M, Mamo D, Uchida H.
    J Clin Psychiatry; 2012 Aug 08; 73(8):1147-52. PubMed ID: 22967779
    [Abstract] [Full Text] [Related]

  • 16. Dopamine D2 receptor occupancy in vivo by the novel atypical antipsychotic olanzapine--a 123I IBZM single photon emission tomography (SPET) study.
    Pilowsky LS, Busatto GF, Taylor M, Costa DC, Sharma T, Sigmundsson T, Ell PJ, Nohria V, Kerwin RW.
    Psychopharmacology (Berl); 1996 Mar 08; 124(1-2):148-53. PubMed ID: 8935810
    [Abstract] [Full Text] [Related]

  • 17. Optimizing limbic selective D2/D3 receptor occupancy by risperidone: a [123I]-epidepride SPET study.
    Bressan RA, Erlandsson K, Jones HM, Mulligan RS, Ell PJ, Pilowsky LS.
    J Clin Psychopharmacol; 2003 Feb 08; 23(1):5-14. PubMed ID: 12544369
    [Abstract] [Full Text] [Related]

  • 18. A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone.
    Mamo D, Kapur S, Shammi CM, Papatheodorou G, Mann S, Therrien F, Remington G.
    Am J Psychiatry; 2004 May 08; 161(5):818-25. PubMed ID: 15121646
    [Abstract] [Full Text] [Related]

  • 19. Striatal D2/D3 receptor occupancy, clinical response and side effects with amisulpride: an iodine-123-iodobenzamide SPET study.
    Meisenzahl EM, Schmitt G, Gründer G, Dresel S, Frodl T, la Fougère C, Scheuerecker J, Schwarz M, Boerner R, Stauss J, Hahn K, Möller HJ.
    Pharmacopsychiatry; 2008 Sep 08; 41(5):169-75. PubMed ID: 18763218
    [Abstract] [Full Text] [Related]

  • 20. Positron emission tomography measurement of dopamine D₂ receptor occupancy in the pituitary and cerebral cortex: relation to antipsychotic-induced hyperprolactinemia.
    Arakawa R, Okumura M, Ito H, Takano A, Takahashi H, Takano H, Maeda J, Okubo Y, Suhara T.
    J Clin Psychiatry; 2010 Sep 08; 71(9):1131-7. PubMed ID: 20361897
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.